top of page


Allysta Pipeline 2022 v2.jpg

ALY688 Ophthalmic Solution is an ophthalmic formulation of ALY688 suitable for eye drop administration. In relevant animal models, ALY688 reduces levels of pro-inflammatory cytokines and activated T cells on the ocular surface, resulting in reduction in corneal damage as well as improvements in tear volume/tear integrity. ALY688 accelerates epithelial (corneal) healing following injury. By targeting two key aspects of dry eye disease, ALY688 may demonstrate improved activity with efficacy in a broader range of dry eye sufferers. 

ALY688ER is a sustained release systemic formulation of ALY688 formulated for SC administration. It is being evaluated for diseases where a reduction in the levels of native adiponectin protein leads to an imbalance in the regulation of inflammation and/or metabolism, e.g. resulting in an inflammatory response or insulin resistance. Restoring adiponectin balance using a peptide analogue may be of particular benefit in NASH (non-alcoholic steatohepatitis), a disease in which metabolic derangements with fat accumulation in the liver and insulin resistance, and hepatic inflammation and fibrosis, can lead to progressive liver damage. ALY688ER is also being evaluated in relevant animal models of muscles diseases of inflammation and fibrosis/remodeling, including Duchenne's muscular dystrophy and cardiac fibrosis/remodeling.

bottom of page